Momenta Pharmaceuticals, Inc. (MNTA) Shares Sold by Tocqueville Asset Management L.P.
Tocqueville Asset Management L.P. lessened its position in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) by 19.9% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 530,666 shares of the biotechnology company’s stock after selling 131,615 shares during the quarter. Tocqueville Asset Management L.P. owned approximately 0.68% of Momenta Pharmaceuticals worth $13,957,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. SG Americas Securities LLC purchased a new position in Momenta Pharmaceuticals during the second quarter valued at $108,000. Sawtooth Solutions LLC purchased a new position in Momenta Pharmaceuticals during the third quarter valued at $227,000. Pillar Pacific Capital Management LLC bought a new stake in shares of Momenta Pharmaceuticals in the 3rd quarter worth $231,000. Laurion Capital Management LP bought a new stake in shares of Momenta Pharmaceuticals in the 2nd quarter worth $284,000. Finally, Essex Investment Management Co. LLC bought a new stake in shares of Momenta Pharmaceuticals in the 3rd quarter worth $330,000. Institutional investors own 95.71% of the company’s stock.
Momenta Pharmaceuticals stock opened at $11.84 on Friday. The firm has a market capitalization of $877.52 million, a price-to-earnings ratio of -10.07 and a beta of 2.31. Momenta Pharmaceuticals, Inc. has a 12 month low of $10.10 and a 12 month high of $32.20.
In related news, CEO Craig A. Wheeler sold 4,374 shares of Momenta Pharmaceuticals stock in a transaction on Monday, November 12th. The stock was sold at an average price of $13.50, for a total value of $59,049.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold 8,136 shares of company stock valued at $106,026 in the last ninety days. 4.80% of the stock is currently owned by corporate insiders.
A number of research firms have commented on MNTA. BidaskClub lowered Momenta Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, October 4th. ValuEngine raised Momenta Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, November 1st. Cantor Fitzgerald set a $24.00 target price on Momenta Pharmaceuticals and gave the stock a “hold” rating in a report on Wednesday, October 10th. Zacks Investment Research raised Momenta Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, October 8th. Finally, Stifel Nicolaus set a $39.00 target price on Momenta Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, November 7th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $27.00.
ILLEGAL ACTIVITY NOTICE: “Momenta Pharmaceuticals, Inc. (MNTA) Shares Sold by Tocqueville Asset Management L.P.” was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this story on another site, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be read at https://www.watchlistnews.com/momenta-pharmaceuticals-inc-mnta-shares-sold-by-tocqueville-asset-management-l-p/2668507.html.
Momenta Pharmaceuticals Company Profile
Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the United States. The company's complex generics programs include Enoxaparin sodium injection, a generic version of Lovenox that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing-remitting multiple sclerosis; and GLATOPA, a generic product candidate for three-times-weekly COPAXONE.
Featured Article: What is cost of equity?
Want to see what other hedge funds are holding MNTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA).
Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.